Cyxone step up activities and extend collaboration with global CRO around RA trial

Cyxone (publ) announces today that the company has signed a Letter of Agreement (LOA) with the internationally renowned clinical contract research organization (CRO) following on an early operations agreement (EOA) signed last month. The LOA is a key step for advancing the clinical phase 2b trial of Rabeximod in patients with rheumatoid arthritis

The agreement enables Cyxone to expand and intensify start-up activities for the phase 2b trial including site selections and regulatory submissions enabling an efficient route to enrolling patients into the trial within the shortest period of time.

Cyxone is developing Rabeximod, an oral potential second line treatment for patients suffering from the autoimmune disease rheumatoid arthritis (RA) and who do not respond to current standard of care treatments. This underserved patient population represents 25-40% of diagnosed patients. Based on previous preclinical and clinical results, the company is currently preparing for a phase 2b trial of Rabeximod in patients with RA. The trial will be double blind, randomized, placebo controlled consisting of three treatment arms comparing two different dose levels of Rabeximod on top standard treatment with methotrexate alone over a 16-week-treatment period with an 8-week extension and 2-week follow up.

"Following on an early clinical operations agreement which was signed in December, we quickly advance our collaboration with this Letter of Agreement; a signal of commitment from both parties. Cyxone has secured a partner with first-class rheumatoid arthritis trial expertise and a global network of research sites able to deliver efficiently and at the highest level of quality for the phase 2b trial," comments Tara Heitner, CEO, Cyxone.


Tara Heitner, CEO
Tel: +46 70 781 88 08
Email: [email protected]
Adelgatan 21
211 22 Malmö, Sweden

Forward-looking statements

This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.

About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB, +46(0)8-528 00 399, [email protected] For more information, please visit 

Nerladdningsbara filer

First Berlin Equity Research publicerar oberoende analys av Cyxone

Cyxone (publ), ett bioteknikföretag inom autoimmuna sjukdomar, meddelar idag att det internationellt renommerade analyshuset First Berlin har publicerat en oberoende analysrapport av bolaget.

Kommuniké från årsstämma i Cyxone AB den 16 maj 2022

Idag, den 16 maj 2022, hölls årsstämma i Cyxone AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet.

Cyxone AB rapporterar lovande terapieffekt av T20K/KORa kombinationsbehandling i en terapeutisk preklinisk modell av MS

Cyxone AB (CYXO), ett företag i klinisk fas som utvecklar transformativa terapier inom det autoimmuna området för att förse patienter med förbättrade behandlingsalternativ, meddelade idag resultat från sitt pågående samarbete med Medical University of Vienna.

Cyxone offentliggör framåtblickande strategi för läkemedelsutveckling med fokus på Rabeximod i studie på patienter med reumatoid artrit

Cyxone AB (CYXO), ett företag i klinisk fas som utvecklar transformativa behandlingar inom det autoimmuna området för att förbättra behandlingsresultatet för patienter, publicerade idag en framåtblickande strategi.

Kallelse till årsstämma i Cyxone AB

Aktieägarna i Cyxone AB, org. nr 559020-5471 ("Cyxone"), kallas härmed till årsstämma i Quality Hotel Views lokaler på Hyllie Stationstorg 29 i Malmö, måndagen den 16 maj 2022 kl. 10.00.

Notice of annual general meeting in Cyxone AB

The English text is an unofficial translation. In case of any discrepancies between the Swedish language version of this document and the English translation, the Swedish language version shall prevail.

The shareholders in Cyxone AB, Reg. No. 559020-5471 ("Cyxone"), are hereby invited to the annual general meeting to be held at the premises of Quality Hotel View at Hyllie Stationstorg 29 in Malmö, Sweden on Monday 16 May 2022 at 10:00 CEST.

Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Nybrogatan 34
Box 5216
102 45 Stockholm

08-692 21 90

Om beQuoted